TUSTIN, CA -- (MARKET WIRE) -- 02/28/11 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that data from four studies investigating the company's lead phosphatidylserine (PS)-targeting clinical candidate bavituximab and other PS-targeting antibodies have been accepted for poster presentation at the 102nd Annual Meeting of the American Association for Cancer Research (AACR) to be held in Orlando, Florida, April 2-6, 2011.
Abstracts Accepted at AACR:
Title: Targeting Phosphatidylserine to Improve Androgen Deprivation Therapy of Prostate Cancer
Authors: Yi Yin and Philip E. Thorpe
Presentation Time: Sunday, April 3, 2011, 1:00 - 5:00 PM ET
Location: Exhibit Hall A4-C, Poster Section 26
Title: Phosphatidylserine-Targeting Antibody Induces Differentiation of Myeloid-Derived Suppressor Cells into M1-Like Macrophages
Authors: Xianming Huang, Dan Ye, and Philip E. Thorpe
Presentation Time: Tuesday, April 5, 2011, 8:00 AM -12:00 PM ET
Location: Exhibit Hall A4-C, Poster Section 31
Title: Phosphatidylserine-Targeting Antibody Combined with Sorafenib has Strong Anti-Tumor Activity against Human Hepatocellular Carcinomas in Mice
Authors: Xiaoyun Cheng and Philip E. Thorpe
Presentation Time: Tuesday, April 5, 2011, 8:00 AM -12:00 PM ET
Location: Exhibit Hall A4-C, Poster Section 30
Title: Monitoring Tumor Response to Chemotherapy by In Vivo Real-Time Imaging of Phosphatidylserine Targeting Antibodies
Authors: Jian Gong, Linda Him, Christopher Hughes, and Bruce Freimark
Presentation Time: Wednesday, April 6, 2011, 8:00 AM -12:00 PM ET
Location: Exhibit Hall A4-C, Poster Section 5
For additional information on the 102nd Annual Meeting of the AACR, please visit: http://www.aacr.org/home/scientists/meetings--workshops/aacr-102nd-annual-meeting-2011.aspx
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Peregrine Contact:
Amy FigueroaPeregrine Pharmaceuticals
(800) 987-8256
info@peregrineinc.com
Source: Peregrine Pharmaceuticals
News Provided by Acquire Media